This STAT5 cleavage inhibition is concurrent with a decrease in both the membrane level of FATP2 (MSC2 cells and PMN-MDSC) in vitro and the anti-tumor effect of doxorubicin/GTN combination in vivo. The gene discussed is SLC27A2; the disease is neoplasm.